Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesPrecision BioSciences Inc

Precision BioSciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
10.6 USD 0.73 ( 7.40%)
Last update at 2026-11-06T21:05:00Z
VOLUME
1228224
Market Cap
191.98M

Momentum Score

…

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.07
Low
10.78
High
52 Week Price Range
3.53
Low
8.82
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Precision BioSciences is a clinical-stage genome editing company that uses its ARCUS nuclease platform to develop in vivo and ex vivo therapies for genetic diseases and oncology. The proprietary, compact nuclease and platform-based pipeline, plus clinical progress, could support long-term growth and may appeal to investors seeking exposure to gene editing.
Major risks are clinical and regulatory failure, high cash burn and financing needs, strong competition from other gene-editing technologies, and manufacturing or delivery challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
9.87
Dividend Yield
-
Revenue TTM
34.26M
Revenue Per Share
2.67
Gross Profit TTM
34.26M
Debt / Equity
0.31
ROE
-62.71%
Net Debt
-82.02M
ROCE
-35.84%
Diluted EPS TTM
-3.63

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -46.61M 7.17M -42.53M -111.64M -30.60M
Net income -46.61M 7.17M -61.32M -122.91M -30.92M
Selling general administrative 32.24M 35.30M 39.09M 41.52M 39.69M
Selling and marketing expenses - - 4.23M - -
Gross profit 31.51M 68.70M 48.73M 25.10M 115.53M
Reconciled depreciation 2.75M 4.58M 8.97M 9.00M 10.20M
Ebit -52.15M 8.95M -40.30M -100.37M -39.40M
Ebitda -49.40M 13.53M -32.04M -98.47M -28.81M
Depreciation and amortization 2.75M 4.58M 8.26M 1.89M 10.59M
Non operating income net other - - - -11.27M 8.80M
Operating income -52.15M -26.16M -43.74M -100.37M -39.40M
Other operating expenses 86.41M 94.86M 92.46M 125.46M 154.93M
Interest expense 1.42M 1.78M 2.23M 1.11M 0.13M
Interest income 4.24M 6.76M 7.80M 3.47M 0.21M
Net interest income 2.82M 4.98M 5.66M 2.36M 0.08M
Income tax expense - - 27.24M 11.27M 0.32M
Total revenue 34.26M 68.70M 48.73M 25.10M 115.53M
Total operating expenses 83.66M 94.86M 92.46M 125.46M 154.93M
Cost of revenue 2.75M 4.58M 8.26M - -
Total other income expense net 5.54M 33.33M 1.21M -11.27M 8.80M
Net income from continuing ops -46.61M 7.17M -87.25M -111.64M -30.60M
Net income applicable to common shares - - - -111.64M -30.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 154.42M 136.39M 159.78M 238.17M 211.50M
Intangible assets 1.17M 0.62M 0.40M 1.35M 2.05M
Other current assets 3.15M 6.98M 6.88M 1.26M 0.17M
Total liab 62.17M 80.00M 140.92M 177.74M 120.33M
Total stockholder equity 92.25M 56.39M 18.86M 60.43M 91.17M
Other current liab 7.11M 9.39M 11.44M 10.21M 11.77M
Common stock 0.00M 0.00M 0.00M 0.00M -
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -528.19M -482.46M -489.63M -428.31M -316.68M
Other liab - - - 93.07M 77.06M
Other assets - - 0.00M 9.80M 11.52M
Cash 110.82M 85.90M 116.68M 189.58M 143.66M
Total current liabilities 8.91M 14.98M 49.99M 59.66M 35.98M
Current deferred revenue - 2.96M 12.04M 46.19M 21.24M
Net debt -82.02M -55.85M -85.41M -162.54M -134.55M
Short term debt 1.51M 1.32M 23.55M 2.04M 1.82M
Short long term debt - - 22.41M - -
Short long term debt total 28.81M 30.05M 31.27M 27.04M 9.11M
Other stockholder equity 620.43M 538.86M 508.49M 488.74M 407.84M
Property plant equipment - - - 20.19M 25.15M
Total current assets 118.74M 94.99M 136.36M 199.10M 161.75M
Long term investments 0.74M 3.21M 3.21M 9.41M 10.63M
Net tangible assets - - - 59.09M 89.12M
Short term investments 4.76M 0.41M - - -
Net receivables 0.00M 1.70M 12.80M 0.72M 0.49M
Long term debt 22.40M 22.32M - 22.22M 2.48M
Inventory - - - 7.55M 17.43M
Accounts payable 0.30M 1.31M 2.97M 1.23M 1.14M
Retained earnings total equity - - - -428.31M -316.68M
Treasury stock - - - -0.95M -0.95M
Non currrent assets other 26.54M 27.39M 0.23M 9.80M 4.64M
Non current assets total 35.68M 41.40M 23.42M 39.06M 49.74M
Capital lease obligations 6.40M 7.72M 8.86M 4.81M 6.63M
Long term debt total - - - 22.22M 2.48M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.21M 5.16M -3.32M -5.80M
Change to liabilities - - - 0.15M 0.87M
Total cashflows from investing activities -0.63M -0.21M 5.83M -3.32M -5.80M
Net borrowings 0.00M -0.04M 0.00M 19.80M -0.05M
Total cash from financing activities 95.16M 50.45M 5.39M 94.98M 70.52M
Change to operating activities - - - -3.17M 2.37M
Net income -45.72M 7.17M -61.32M -111.64M -30.60M
Change in cash 28.68M -8.21M -72.90M 45.91M 53.87M
Begin period cash flow 108.47M 116.68M 189.58M 143.66M 89.80M
End period cash flow 137.15M 108.47M 116.68M 189.58M 143.66M
Total cash from operating activities -65.84M -58.45M -84.11M -45.75M -10.85M
Issuance of capital stock 94.94M 50.24M 2.16M 74.34M 60.48M
Depreciation 2.75M 4.58M 8.26M 9.00M 10.20M
Other cashflows from investing activities -0.55M -0.03M 0.11M - -0.75M
Change to inventory - - - - 4.30M
Change to account receivables 0.23M 10.42M -0.18M -0.23M 9.51M
Sale purchase of stock - - - 74.74M 67.26M
Other cashflows from financing activities 95.16M 0.25M 0.40M 20.64M 12.54M
Change to netincome - - - 32.83M -10.08M
Capital expenditures 0.09M 0.25M 2.28M 3.32M 5.80M
Change receivables - - - -0.23M 9.51M
Cash flows other operating - - - 25.04M 10.41M
Cash and cash equivalents changes - - - 45.91M 53.87M
Change in working capital -24.71M -54.00M -41.49M 24.11M 19.58M
Stock based compensation 10.19M 12.60M 14.04M 19.20M 16.51M
Other non cash items -8.35M -28.79M -3.60M 13.57M -20.40M
Free cash flow -65.93M -58.70M -86.39M -49.07M -16.66M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DTIL
Precision BioSciences Inc		 0.73
7.40%		 10.60 - 14.08 5.60 2.12 3.18 -0.27
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Precision BioSciences Inc

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

302 East Pettigrew St., Durham, NC, United States, 27701

919 314 5512

https://precisionbiosciences.com

68

Name Title Year Born
Mr. Michael Amoroso Pres, CEO & Director 1978
Dr. Derek Jantz Ph.D. Co-Founder, Chief Scientific Officer & Strategy 1976
Mr. John Alexander Kelly Chief Financial Officer 1967
Dr. Jefferson J. Smith Ph.D. Co-Founder & Chief Research Officer NA
Mr. Shane Barton VP, Corp. Controller & Principal Accounting Officer 1971
Mei Burris Director of Investor Relations & Fin. NA
Mr. Dario Scimeca Gen. Counsel & Sec. 1975
Mr. Bruce Stevens VP of Quality & Compliance NA
Ms. Heather King Director of Marketing Communications & PR NA
Maurissa Messier Sr. Director of Corp. Communications NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…